| Literature DB >> 32774308 |
Sungkean Kim1, Yong-Wook Kim2,3, Miseon Shim4, Min Jin Jin5, Chang-Hwan Im3, Seung-Hwan Lee2,6.
Abstract
BACKGROUND: Pathologies of schizophrenia and bipolar disorder have been poorly understood. Brain network analysis could help understand brain mechanisms of schizophrenia and bipolar disorder. This study investigates the source-level brain cortical networks using resting-state electroencephalography (EEG) in patients with schizophrenia and bipolar disorder.Entities:
Keywords: cortical functional network; graph theory; ipolar disorder; resting-state EEG; schizophrenia
Year: 2020 PMID: 32774308 PMCID: PMC7388793 DOI: 10.3389/fpsyt.2020.00661
Source DB: PubMed Journal: Front Psychiatry ISSN: 1664-0640 Impact factor: 4.157
Demographic characteristics of study participants.
| SZ(N = 38) | BP(N = 34) | HC(N = 30) |
| Post-hoc(Bonferroni) | |
|---|---|---|---|---|---|
| Age (years) | 43.16 ± 11.16 | 41.44 ± 12.57 | 42.97 ± 12.40 | 0.810 | |
| Sex | 0.141 | ||||
| Male | 16 (42.1) | 9 (26.5) | 15 (50.0) | ||
| Female | 22 (57.9) | 25 (73.5) | 15 (50.0) | ||
| Premorbid IQ | 100.60 ± 10.64 | 98.68 ± 8.15 | 108.23 ± 9.13 | <0.001 | SZ < HC, |
| Education (years) | 12.92 ± 2.73 | 12.79 ± 2.82 | 14.13 ± 3.51 | 0.153 | |
| Number of hospitalizations | 2.84 ± 3.58 | 4.12 ± 10.06 | 0.466 | ||
| Duration of illness (years) | 12.09 ± 7.55 | 10.45 ± 6.96 | 0.371 | ||
| Onset age (years) | 30.06 ± 10.94 | 31.26 ± 12.88 | 0.689 | ||
| Dosage of medication* | 319.21 ± 307.81 | 276.49 ± 410.92 | |||
| Dosage of medication* | 85.53 ± 207.59 | 762.82 ± 463.93 | |||
| PANSS | |||||
| Positive | 8.19 ± 4.89 | 4.56 ± 1.11 | |||
| Negative | 14.27 ± 5.31 | 7.97 ± 2.42 | |||
| Disorganized | 5.68 ± 2.83 | 3.79 ± 1.04 | |||
| Excitation | 7.76 ± 3.44 | 5.03 ± 1.38 | |||
| Depression | 6.68 ± 1.62 | 5.71 ± 2.07 | |||
| Total | 60.92 ± 21.71 | 41.26 ± 8.42 | |||
| YMRS | 5.56 ± 6.37 | ||||
| KAVLT-trial 5 | 8.37 ± 2.79 | 10.61 ± 2.97 | 11.57 ± 1.75 | <0.001 | SZ < BP, |
| KAVLT-delayed recall | 6.11 ± 3.29 | 7.97 ± 3.59 | 9.96 ± 2.01 | <0.001 | SZ < BP, SZ < HC, BP < HC |
| SOFAS | 64.54 ± 12.50 | 72.35 ± 11.76 | 0.009 |
SZ, schizophrenia; BP, bipolar disorder; HC, healthy control; CPZ, chlorpromazine; PANSS, positive and negative syndrome scale; YMRS, Young mania rating scale; KAVLT, Korean auditory verbal learning test; HADS, hospital anxiety and depression scale; SOFAS, social and occupational functioning assessment scale.
*The mean CPZ (p = 0.617) and valproate equivalents reflect all patients (p < 0.001), including the patients who were not receiving the medications.
Mean and standard deviation values of global network indices including strength, clustering coefficient (CC), path length (PL), and efficiency for each frequency band among the schizophrenia, bipolar disorder, and healthy control groups.
| SZ(N = 38) | BP(N = 34) | HC(N = 30) | Effect size(η2) |
|
| Post-hoc(Bonferroni) | |
|---|---|---|---|---|---|---|---|
| Delta band | |||||||
| Strength | 62.242 ± 3.427 | 62.273 ± 3.085 | 61.498 ± 2.953 | 0.027 | 1.303 | 0.277 | |
| CC | 0.414 ± 0.022 | 0.415 ± 0.021 | 0.410 ± 0.019 | 0.024 | 1.160 | 0.318 | |
| PL | 2.551 ± 0.120 | 2.540 ± 0.120 | 2.566 ± 0.118 | 0.021 | 0.974 | 0.381 | |
| Efficiency | 0.417 ± 0.023 | 0.417 ± 0.021 | 0.412 ± 0.020 | 0.027 | 1.303 | 0.277 | |
|
| |||||||
| | 54.161 ± 2.727 | 53.309 ± 2.254 | 51.865 ± 2.074 | 0.156 | 8.594 |
| SZ > HC, BP > HC |
| | 0.357 ± 0.017 | 0.352 ± 0.015 | 0.343 ± 0.013 | 0.148 | 8.095 |
| SZ > HC, BP > HC |
| | 3.000 ± 0.129 | 3.032 ± 0.114 | 3.103 ± 0.110 | 0.136 | 7.318 |
| SZ < HC, BP < HC |
| | 0.362 ± 0.019 | 0.356 ± 0.015 | 0.346 ± 0.014 | 0.156 | 8.608 |
| SZ > HC, BP > HC |
| Alpha band | |||||||
| Strength | 54.634 ± 2.745 | 53.989 ± 2.591 | 53.053 ± 2.178 | 0.064 | 3.167 | 0.047 | |
| CC | 0.360 ± 0.018 | 0.356 ± 0.017 | 0.351 ± 0.014 | 0.056 | 2.769 | 0.068 | |
| PL | 2.968 ± 0.130 | 2.991 ± 0.126 | 3.033 ± 0.111 | 0.047 | 2.288 | 0.107 | |
| Efficiency | 0.365 ± 0.019 | 0.361 ± 0.018 | 0.354 ± 0.015 | 0.064 | 3.176 | 0.046 | |
| Low beta band | |||||||
| Strength | 48.215 ± 3.088 | 48.355 ± 6.175 | 46.773 ± 3.292 | 0.047 | 2.309 | 0.105 | |
| CC | 0.313 ± 0.020 | 0.315 ± 0.042 | 0.305 ± 0.021 | 0.046 | 2.217 | 0.115 | |
| PL | 3.481 ± 0.194 | 3.485 ± 0.322 | 3.571 ± 0.216 | 0.046 | 2.231 | 0.113 | |
| Efficiency | 0.322 ± 0.021 | 0.323 ± 0.042 | 0.313 ± 0.023 | 0.047 | 2.307 | 0.105 | |
| High beta band | |||||||
| Strength | 41.317 ± 4.594 | 41.415 ± 4.358 | 42.645 ± 5.351 | 0.002 | 0.092 | 0.913 | |
| CC | 0.261 ± 0.030 | 0.263 ± 0.030 | 0.272 ± 0.036 | 0.004 | 0.189 | 0.828 | |
| PL | 4.195 ± 0.387 | 4.180 ± 0.389 | 4.095 ± 0.489 | 0.002 | 0.086 | 0.918 | |
| Efficiency | 0.285 ± 0.031 | 0.285 ± 0.029 | 0.292 ± 0.036 | 0.001 | 0.043 | 0.958 | |
| Gamma band | |||||||
| Strength | 30.438 ± 2.152 | 30.425 ± 1.983 | 29.938 ± 2.229 | 0.031 | 1.509 | 0.227 | |
| CC | 0.183 ± 0.013 | 0.184 ± 0.012 | 0.181 ± 0.014 | 0.025 | 1.206 | 0.304 | |
| PL | 5.381 ± 0.386 | 5.391 ± 0.394 | 5.512 ± 0.427 | 0.042 | 2.038 | 0.136 | |
| Efficiency | 0.230 ± 0.017 | 0.229 ± 0.016 | 0.224 ± 0.017 | 0.048 | 2.336 | 0.102 |
*The p-value was adjusted via Bonferroni correction with 0.05/24 = 0.002083.
SZ, schizophrenia; BP, bipolar disorder; HC, healthy control.
Values are in bold to visually highlight them in the table.
Figure 1(A) Brain regions showing significantly different nodal clustering coefficients (CCs) of the theta frequency band among patient groups and healthy controls. (B) Effect sizes of differences in nodal CCs of the theta frequency band among patient groups and healthy controls. Each bar indicates the effect size at each node. The upper bars indicate 74 regions in the left hemisphere and the lower bars indicate 74 regions in the right hemisphere. For reference, three dotted lines are drawn for small (0.01), medium (0.06), and large (0.14) effect sizes. The bars with numbers reveal significant differences among patient groups and the healthy controls (The p-value was adjusted via Bonferroni correction with 0.05/148 = 0.000338). The number “1” denotes brain regions where patient groups show significant differences from healthy controls. The number “2” denotes brain regions where patients with schizophrenia show significant differences from those with bipolar disorder. The number “3” denotes brain regions where patients with schizophrenia show significant differences from healthy controls.
Figure 2Correlations between nodal clustering coefficients (CCs) and psychiatric, clinical, or cognitive measures in the theta band for each group. SOFAS, social and occupational functioning assessment scale; PANSS, positive and negative syndrome scale; KAVLT, Korean auditory verbal learning test.